CL2019000476A1 - Compuestos de heteroarilcarboxamida como inhibidores de ripk2. - Google Patents
Compuestos de heteroarilcarboxamida como inhibidores de ripk2.Info
- Publication number
- CL2019000476A1 CL2019000476A1 CL2019000476A CL2019000476A CL2019000476A1 CL 2019000476 A1 CL2019000476 A1 CL 2019000476A1 CL 2019000476 A CL2019000476 A CL 2019000476A CL 2019000476 A CL2019000476 A CL 2019000476A CL 2019000476 A1 CL2019000476 A1 CL 2019000476A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- heteroarylcarboxamide
- ripk2 inhibitors
- ripk2
- inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A LOS COMPUESTOS DE LA FÓRMULA (I), O SALES DE AQUEL ACEPTABLES DESDE EL PUNTO DE VISTA FARMACÉUTICO, EN DONDE R1, R2, X, Y Y HET SON COMO SE DEFINEN EN LA PRESENTE. LA INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN ESTOS COMPUESTOS, A MÉTODOS PARA USAR ESTOS COMPUESTOS EN EL TRATAMIENTO DE VARIAS ENFERMEDADES Y TRASTORNOS, A PROCESOS PARA PREPARAR ESTOS COMPUESTOS Y A INTERMEDIARIOS ÚTILES EN ESTOS PROCESOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394779P | 2016-09-15 | 2016-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000476A1 true CL2019000476A1 (es) | 2019-05-31 |
Family
ID=59901598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000476A CL2019000476A1 (es) | 2016-09-15 | 2019-02-22 | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US10138241B2 (es) |
| EP (1) | EP3512833B1 (es) |
| JP (1) | JP6733050B2 (es) |
| KR (1) | KR102472736B1 (es) |
| CN (1) | CN110023290B (es) |
| AR (1) | AR109650A1 (es) |
| AU (1) | AU2017327539B2 (es) |
| BR (1) | BR112019003320B1 (es) |
| CL (1) | CL2019000476A1 (es) |
| CO (1) | CO2019001181A2 (es) |
| CY (1) | CY1123494T1 (es) |
| DK (1) | DK3512833T3 (es) |
| EA (1) | EA038128B1 (es) |
| ES (1) | ES2816003T3 (es) |
| HR (1) | HRP20201494T1 (es) |
| HU (1) | HUE051551T2 (es) |
| IL (1) | IL265062B (es) |
| LT (1) | LT3512833T (es) |
| MA (1) | MA46229B1 (es) |
| MX (1) | MX387443B (es) |
| NZ (1) | NZ750416A (es) |
| PE (1) | PE20190979A1 (es) |
| PH (1) | PH12019500497A1 (es) |
| PL (1) | PL3512833T3 (es) |
| PT (1) | PT3512833T (es) |
| RS (1) | RS60729B1 (es) |
| SA (1) | SA519401322B1 (es) |
| SI (1) | SI3512833T1 (es) |
| TW (1) | TWI749062B (es) |
| UA (1) | UA123287C2 (es) |
| WO (1) | WO2018052772A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017273857B2 (en) | 2016-06-01 | 2021-08-19 | Athira Pharma, Inc. | Compounds |
| DK3512833T3 (da) | 2016-09-15 | 2020-10-12 | Boehringer Ingelheim Int | Heteroarylcarboxamidforbindelser som inhibitorer af ripk2 |
| JP6932771B2 (ja) * | 2016-09-15 | 2021-09-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｒｉｐｋ２の阻害剤としてのピリジンおよびピラジン化合物 |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| US11168093B2 (en) * | 2018-12-21 | 2021-11-09 | Celgene Corporation | Thienopyridine inhibitors of RIPK2 |
| AR118471A1 (es) * | 2019-03-22 | 2021-10-06 | Takeda Pharmaceuticals Co | Derivados de pirrol e imidazol fusionados con piridina como inhibidores de ripk2 |
| EP4518974A1 (en) | 2022-06-10 | 2025-03-12 | Interline Therapeutics, Inc. | Imidazo(1,2-a)pyridine derivatives as ripk2 inhibitors |
| WO2024254539A1 (en) | 2023-06-09 | 2024-12-12 | Interline Therapeutics, Inc. | Methods of treating inflammatory diseases |
| WO2024259328A1 (en) * | 2023-06-16 | 2024-12-19 | Odyssey Therapeutics, Inc. | Inhibitors of ripk2 and uses thereof |
| WO2025085928A1 (en) | 2023-10-20 | 2025-04-24 | Odyssey Therapeutics, Inc. | Methods of treating a patient with an inflammatory bowel disease |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE375340T1 (de) | 2001-02-21 | 2007-10-15 | Nps Pharma Inc | Heteropolycyclische verbindungen und deren verwendung als metabotrope glutamatrezeptorantagonisten |
| ATE482200T1 (de) | 2003-05-01 | 2010-10-15 | Bristol Myers Squibb Co | Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen |
| AR060635A1 (es) | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| EP2041116A1 (de) | 2006-07-07 | 2009-04-01 | Boehringer Ingelheim International GmbH | Phenyl substituierte heteroaryl-derivate und deren verwendung als antitumormittel |
| MX2009004900A (es) | 2006-11-09 | 2009-05-19 | Hoffmann La Roche | Arilamidas sustituidas por tiazol u oxazol. |
| US20110009437A1 (en) | 2008-02-27 | 2011-01-13 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Carboxamide-heteroaryl derivatives for the treatment of diabetes |
| CN101671336B (zh) | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 |
| US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
| US20130023532A1 (en) | 2010-03-26 | 2013-01-24 | Casillas Linda N | Indazolyl-pyrimidines as kinase inhibitors |
| JP2013523766A (ja) * | 2010-03-31 | 2013-06-17 | グラクソ グループ リミテッド | キナーゼ阻害剤としてのイミダゾリル‐イミダゾール |
| WO2012080376A1 (en) | 2010-12-17 | 2012-06-21 | Syngenta Participations Ag | Insecticidal compounds |
| CN103354811A (zh) | 2011-02-09 | 2013-10-16 | 先正达参股股份有限公司 | 杀虫化合物 |
| AR091490A1 (es) | 2012-06-19 | 2015-02-11 | Bristol Myers Squibb Co | Antagonistas de iap |
| AR092529A1 (es) | 2012-09-13 | 2015-04-22 | Glaxosmithkline Llc | Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento |
| TW201427668A (zh) | 2012-11-20 | 2014-07-16 | Celgene Avilomics Res Inc | 治療和布魯頓（ｂｒｕｔｏｎ’ｓ）酪胺酸激酶相關之疾病或失調的方法 |
| WO2014122083A1 (de) * | 2013-02-06 | 2014-08-14 | Bayer Cropscience Ag | Halogensubstituierte pyrazolderivate als schädlingsbekämpfungsmittel |
| EP2968276A4 (en) | 2013-03-15 | 2017-02-15 | President and Fellows of Harvard College | Hybrid necroptosis inhibitors |
| AU2014337044A1 (en) | 2013-10-18 | 2016-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CA2935646A1 (en) | 2014-01-03 | 2015-07-09 | Bayer Animal Health Gmbh | Novel pyrazolyl-heteroarylamides as pesticides |
| US10239881B2 (en) * | 2014-10-27 | 2019-03-26 | University Health Network | RIPK2 inhibitors and method of treating cancer with same |
| PL3504187T3 (pl) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd. | Stosowanie pridopidyny w leczeniu zaburzeń czynnościowych |
| DK3512833T3 (da) | 2016-09-15 | 2020-10-12 | Boehringer Ingelheim Int | Heteroarylcarboxamidforbindelser som inhibitorer af ripk2 |
| JP6932771B2 (ja) | 2016-09-15 | 2021-09-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｒｉｐｋ２の阻害剤としてのピリジンおよびピラジン化合物 |
-
2017
- 2017-09-06 DK DK17768914.8T patent/DK3512833T3/da active
- 2017-09-06 EP EP17768914.8A patent/EP3512833B1/en active Active
- 2017-09-06 HU HUE17768914A patent/HUE051551T2/hu unknown
- 2017-09-06 BR BR112019003320-3A patent/BR112019003320B1/pt active IP Right Grant
- 2017-09-06 JP JP2019514206A patent/JP6733050B2/ja active Active
- 2017-09-06 CN CN201780056054.1A patent/CN110023290B/zh active Active
- 2017-09-06 KR KR1020197010671A patent/KR102472736B1/ko active Active
- 2017-09-06 AU AU2017327539A patent/AU2017327539B2/en active Active
- 2017-09-06 HR HRP20201494TT patent/HRP20201494T1/hr unknown
- 2017-09-06 US US15/696,540 patent/US10138241B2/en active Active
- 2017-09-06 SI SI201730450T patent/SI3512833T1/sl unknown
- 2017-09-06 LT LTEP17768914.8T patent/LT3512833T/lt unknown
- 2017-09-06 RS RS20201022A patent/RS60729B1/sr unknown
- 2017-09-06 MX MX2019003026A patent/MX387443B/es unknown
- 2017-09-06 PL PL17768914T patent/PL3512833T3/pl unknown
- 2017-09-06 NZ NZ750416A patent/NZ750416A/en unknown
- 2017-09-06 ES ES17768914T patent/ES2816003T3/es active Active
- 2017-09-06 WO PCT/US2017/050197 patent/WO2018052772A1/en not_active Ceased
- 2017-09-06 MA MA46229A patent/MA46229B1/fr unknown
- 2017-09-06 PE PE2019000500A patent/PE20190979A1/es unknown
- 2017-09-06 PT PT177689148T patent/PT3512833T/pt unknown
- 2017-09-06 UA UAA201903410A patent/UA123287C2/uk unknown
- 2017-09-06 EA EA201990678A patent/EA038128B1/ru not_active IP Right Cessation
- 2017-09-14 AR ARP170102539A patent/AR109650A1/es not_active Application Discontinuation
- 2017-09-14 TW TW106131512A patent/TWI749062B/zh not_active IP Right Cessation
-
2018
- 2018-10-12 US US16/158,407 patent/US11130754B2/en active Active
-
2019
- 2019-02-08 CO CONC2019/0001181A patent/CO2019001181A2/es unknown
- 2019-02-22 CL CL2019000476A patent/CL2019000476A1/es unknown
- 2019-02-26 IL IL265062A patent/IL265062B/en active IP Right Grant
- 2019-03-07 PH PH12019500497A patent/PH12019500497A1/en unknown
- 2019-03-14 SA SA519401322A patent/SA519401322B1/ar unknown
-
2020
- 2020-10-22 CY CY20201101004T patent/CY1123494T1/el unknown
-
2021
- 2021-08-24 US US17/409,956 patent/US12139484B2/en active Active
-
2024
- 2024-10-01 US US18/903,058 patent/US20250042901A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019000476A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2. | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| ECSP18083519A (es) | Inhibidores de bromodominios | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
| MX2017000450A (es) | Compuestos terapeuticos inhibidores. | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| CU24389B1 (es) | Compuestos de heterociclilo bicíclico como inhibidores de irak4 | |
| MX2016013052A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4. | |
| UY36170A (es) | Compuestos de dihidroisoquinolinona sustituida | |
| ECSP17021897A (es) | Compuestos y composiciones como inhibidores de quinasa raf | |
| SV2017005434A (es) | 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CL2017000040A1 (es) | Inhibidores de aldosterona sintasa. | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| SV2017005354A (es) | Derivados de quinolizinona como inhibidores de pi3k | |
| CL2017000827A1 (es) | Inhibidores de aldosterona sintasa | |
| DOP2019000221A (es) | Derivados de pirazol como inhibidores de bromodominio | |
| MX2017003788A (es) | Derivados de nucleósidos sustituidos con 4´-vinilo como inhibidores de la replicación del arn del virus respiratorio sincitial. | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| MX2016016061A (es) | 2,2,2-trifluoroetil-tiadiazinas. | |
| CR20190028A (es) | Compuestos heterocíclicos como inmunomoduladores |